Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy

CD44v6 is overexpressed in a variety of cancers, rendering it a promising target for radio-immunotherapy (RIT). In this study, we have characterized a novel engineered recombinant monoclonal anti-CD44v6 antibody, AbN44v6, and assessed its potential for use in RIT using either (177)Lu or (131)I as th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortensen, Anja C., Spiegelberg, Diana, Haylock, Anna-Karin, Lundqvist, Hans, Nestor, Marika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919712/
https://www.ncbi.nlm.nih.gov/pubmed/29658563
http://dx.doi.org/10.3892/ijo.2018.4364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919712/
https://www.ncbi.nlm.nih.gov/pubmed/29658563
http://dx.doi.org/10.3892/ijo.2018.4364

Ejemplares similares